FDA Inspection 979157 — Diamond Institute For Infertility And Menopause

Diamond Institute For Infertility And Menopause — FEI 3003945103

The FDA completed an inspection of Diamond Institute For Infertility And Menopause on Jul 6, 2016 in Millburn, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 11 citations were issued during this inspection. Product area: Biologics.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Jul 6, 2016
Fiscal Year
2016
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Millburn, NJ (United States)

Citations

IDCFRDescription
1221321 CFR 1271.47(a)Testing, screening, donor eligibility procedures
1222221 CFR 1271.47(a)Design of procedures to ensure compliance
1222321 CFR 1271.47(b)Review and approval of procedures
1223021 CFR 1271.50(a)Responsible person to determine, document
1223821 CFR 1271.55(b)(1)Statement re: certified testing lab
1224121 CFR 1271.55(b)(4)Reasons for ineligibility on summary
1224221 CFR 1271.55(c)Name and personal info on accompanying records
1227521 CFR 1271.65(c)Nonclinical use--label requirements
1227721 CFR 1271.75(a)(1)Risk factors, clinical evidence
1228621 CFR 1271.80(b)Specimen collections not timely
1249621 CFR 1271.85(b)(2)SOP for release; reactive for CMV

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.